NanoGroup plans IPO in H2

Biotech company NanoGroup filed its prospectus to the Financial Market Authority (KNF) and plans IPO in the second half of the year, company's CEO Marek Borzestowski informed. “We plan to use the funds from the IPO to finance development of our projects concerning oncological prevention and treatment, as well as in transplantalogy and to invest in new projects,” Borzestowski said. NanoGroup consists of three subsidaries, NanoVelos (innovative drug delivery system), NanoSanguis (artificial blood project) and NanoThea (radiopharmaceuticals).